市場調查報告書
商品編碼
1284263
2028 年醫藥過濾市場預測——按產品、技術、類型、應用和地區分列的全球分析Pharmaceutical Filtration Market Forecasts to 2028 - Global Analysis By Product, Technique, Type, Application and By Geography |
根據 Stratistics MRC 的數據,2022 年全球製藥過濾市場規模將達到 223 億美元,預計到 2028 年將達到 451 億美元,預測期內復合年增長率為 12.4%。成長於
製藥過濾是一種分離程序,其中處理過的材料通過過濾膜以從中提取不需要的顆粒。 這種過濾技術有助於從介質和溶液中去除空氣中的顆粒。 此外,還使用過濾器從固體、空氣、液體和氣體中去除顆粒物和細菌等污染物。 製藥過濾技術還常用於其他幾個領域,包括最終產品加工、水淨化、原料過濾、細胞分離和空氣淨化。
根據 Evaluate Pharma 的數據,2014 年全球醫藥研發支出價值 1440 億美元,預計到 2028 年這一數字將達到 2850 億美元。
為確保最終產品的完整性和質量,製藥公司必須保持高清潔度標準。 在製造過程中,依賴過濾系統從液體和氣體中去除污染物和雜質。 對高質量藥品不斷增長的需求以及滿足監管要求的需求預計將推動市場增長。
製造過濾設備或系統需要大量的前期資金。 其他因素如勞動力成本和專業知識也包含在製造成本中。 大型切向流過濾系統很昂貴,但安裝整個製造綜合體的上游和下游成本更高。 資本密集型市場特徵會阻礙市場擴張。
仿製藥開發的研發活動不斷增加,以及對單克隆抗體、治療性蛋白質和疫苗等各種醫療保健療法的研究,為市場帶來了增長機會。 增加政府支出以支持研發活動預計也將推動市場增長。
藥品和生物製藥的製造受到嚴格監管。 在許多國家/地區,製造過程每個階段的藥品衛生和質量都受到嚴格的監管。 因此,在傳統機器上製造藥品和生物製藥非常昂貴且困難。 製藥過濾市場的發展受到製藥行業嚴格監管的阻礙。
使用更複雜類型的製藥過濾設備是 COVID-19 更加重視製藥行業的安全標準和質量的結果。 一次性過濾技術還可以防止交叉污染,因此大流行促進了其在製藥行業的使用,重振了製藥過濾市場。 在大流行封鎖期間,全球大多數藥用過濾器製造商都已停止生產其產品。
膜過濾器具有精確且均勻的孔徑分佈,可確保始終如一的過濾質量,這有望在該領域帶來有利可圖的增長。 膜過濾器也可以由多種材料製成,使其適用於製藥應用。 此外,膜過濾器符合製藥生產指南。
微濾部分由於其多功能性和從生物製藥中去除各種雜質的綜合能力,預計在預測期內將以最快的複合年增長率增長。 此外,這種方法可以過濾掉顆粒和污染物,而不會對介質穩定性或生物活性產生不利影響。 此外,微濾系統製造商正在採取戰略行動來支持市場。
由於對製藥過濾產品的需求激增以及對製藥和生物製藥行業的投資增加,預計亞太地區在預測期內將佔據最大的市場份額。 此外,研發部門的發展、醫改的進步、醫療基礎設施的完善、疾病的傳播、醫療行業的技術發展,都在促進市場的擴大。
由於採用了創新的新技術,預計歐洲在預測期內的複合年增長率最高。 此外,由於對生物製藥的需求不斷增長和醫療保健行業的發展,市場正在擴大。 此外,該地區強大的分銷網絡支持製藥過濾行業在該地區的擴張和發展。
2023 年 1 月,Sartorius AG(德國)和 RoosterBio, Inc.(美國)達成合作協議,為基於外泌體的療法提供純化解決方案並建立可擴展的下游製造工藝。
2022 年 6 月,Donaldson Company Inc.(美國)收購了 Purilogics, LLC(美國),這是一家生產膜色譜產品的早期生物技術公司。 此次收購將使公司能夠獲得範圍廣泛的生物製劑純化工具。
According to Stratistics MRC, the Global Pharmaceutical Filtration Market is accounted for $22.3 billion in 2022 and is expected to reach $45.1 billion by 2028 growing at a CAGR of 12.4% during the forecast period. Pharmaceutical filtration is a separation procedure in which processed materials are passed through a filtration membrane in order to extract undesirable particles from them. This filtration technique aids in removing suspended particles from a medium or solution. Additionally, pollutants like particle matter and bacteria are eliminated from solids, air, liquids, and gases using filters. The processing of final products, water purification, raw material filtration, cell separation, and air purification are a few other fields where pharmaceutical filtration techniques are commonly used.
According to Evaluate Pharma, worldwide pharmaceutical R&D spending was valued at USD 144 billion in 2014, and this figure is estimated to reach USD 285 billion by 2028.
To ensure the integrity and quality of the ultimate product, pharmaceutical businesses must maintain high cleanliness standards. The removal of pollutants and impurities from liquids and gases during production depends on the filtering systems. The rising demand for high-quality pharmaceutical products, as well as the need to meet regulatory requirements, is expected to drive market growth.
The production of filtering equipment or systems requires a significant upfront financial expenditure. The cost of labour and other components such as technical expertise go into total manufacturing expenses. Large tangential flow filtration systems are expensive, but it costs more to put up a whole manufacturing complex with both upstream and downstream operations. The market's capital-intensive nature could impede market expansion.
The increase in the number of research and development activities for developing generic pharmaceuticals and researching various healthcare therapies such as monoclonal antibodies, therapeutic proteins, and vaccines represents a growth opportunity for the market. The government increased spending to assist research and development activities is also projected to drive market growth.
Pharmaceutical and biopharmaceutical manufacturing is closely regulated. The sanitation and quality of medications at each stage of the manufacturing process are governed by tight rules in a number of nations. As a result, producing medicines and biopharmaceuticals with conventional machinery is very expensive and difficult. The development of the pharmaceutical filtration market is hampered by the stringent regulations in the pharmaceutical sector.
The usage of more sophisticated types of pharmaceutical filtration devices is a result of COVID-19's greater emphasis on safety standards and quality within the pharmaceutical business. Because single-use filtering technologies can prevent cross-contamination, the pandemic also saw an increase in their use in the pharmaceutical industry, which helped the market for pharmaceutical filtration. During the pandemic lockdown, the majority of pharmaceutical filter manufacturers in the world stopped producing their products.
The membrane filters segment is estimated to have a lucrative growth, due to the capability of membrane filters to have a precise and uniform pore size distribution ensuring a consistent filtration quality. Membrane filters can also be created from a variety of materials, making them adaptable for use in pharmaceutical applications. Membrane filters also follow the manufacturing guidelines for pharmaceutical businesses.
The microfiltration segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its versatility and overall ability to remove a wide range of impurities from biopharmaceutical products. The method also filters out particles and contaminants without adversely affecting the medium's stability or biological activity. Additionally, producers of microfiltration systems are taking strategic actions that will support the market.
Asia Pacific is projected to hold the largest market share during the forecast period owing to surge in demand for pharmaceutical filtration products and rise in investments in the pharmaceutical and biopharmaceutical industry. In addition, the development of the R&D sector, the rise in healthcare reforms, improvements in healthcare infrastructure, rising disease prevalence, and technical developments in the healthcare industry all contribute to the market's expansion.
Europe is projected to have the highest CAGR over the forecast period, owing to the adoption of innovative and latest technologies. The market is also expanding as a result of the rising demand for biopharmaceuticals and the development of the healthcare industry. The expansion and development of the pharmaceutical filtration industry in the region is also being aided by the region's robust distribution network.
Some of the key players profiled in the Pharmaceutical Filtration Market include Meissner Filtration Products, Inc., Parker Hannifin Corp., Merck KGaA, 3M Company, Eaton Corporation PLC, Thermo Fisher Scientific Inc., Danaher, Amazon Filters Ltd., Graver Technologies, Sartorius AG., GE Healthcare, Pall Corporation, Donaldson Company, Inc., Repligen Corporation and Membrane Solutions.
In January 2023, Sartorius AG (Germany) and RoosterBio, Inc. (US) signed a collaboration deal to provide purification solutions and establish scalable downstream manufacturing processes for exosome-based therapies.
In June 2022, Donaldson Company Inc. (US) acquired Purilogics, LLC (US), an early-stage biotechnology company that manufactures membrane chromatography products. Through this acquisition, the company will have access to the purification tools for a wide range of biologics.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.